⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329136 | 1.00 | — | — | |
| SCHEMBL1241366 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3036667 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL3036663 | 0.98 | — | — | |
| SCHEMBL20337456 | 0.94 | OPRM1 (0.33) | — | |
| SCHEMBL12200376 | 0.88 | NPC1 (0.34) | — | |
| SCHEMBL13652632 | 0.88 | — | — | |
| SCHEMBL20337398 | 0.87 | — | — | |
| SCHEMBL23329108 | 0.87 | — | — | |
| SCHEMBL23329110 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724430-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | Flagship Pioneering Innovations VI, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024254396-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118488954-A | Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors | 拜斯丽治疗有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-117580829-A | Quinoline and azaquinolines as inhibitors of CD38 | 勃林格英格翰国际有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4284511-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4132919-A1 | CD38 INHIBITORS | Mitobridge, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20230025807-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-01-26 | — | — | US | disclosed |
| WO-2022165114-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2008119721-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |